Testing effectiveness (Phase 2)Study completedNCT02298933
What this trial is testing
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Who this might be right for
ThrombocytopeniaAlloimmune Platelet Refractoriness
National Heart, Lung, and Blood Institute (NHLBI) 10